All In Biotech

Drug Trial Radar · NCT06481410

Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock

Exploratory Study on the Efficacy and Safety of Methylene Blue in Treating Severe Septic Shock Patients: A Prospective, Randomized, Controlled Trial

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 488 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

488

Planned (sponsor's estimate)

Start

Jun 22, 2024

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Yuyao People's Hospital; Taizhou Enze Medical Center Group; Ningbo Medical Center Lihuili Hospital; Nanning Second People's Hospital
First posted
Jul 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate whether methylene blue injection can safely and effectively improve the survival rate of patients with severe septic shock, shorten the duration of norepinephrine use, reduce the dosage of vasopressors, promptly correct hemodynamics, and improve tissue perfusion and organ function impairment.

Conditions

  • Septic Shock
  • Methylene Blue
  • Sepsis

Interventions

  • Methylene Blue Intervention GroupDrug

    In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.

  • Normal Saline Control GroupDrug

    In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day survival rate of enrolled patientsTime frame: 28-day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.